FAQ

niraparib

Known as: 2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide 
An inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Niraparib inhibits PARP activity, enhancing the… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
051020122018

Related topics

Related topics

5 relations

Broader (3)

IndazolesPiperidinesPoly(ADP-ribose) Polymerase Inhibitors

Narrower (1)

MK 4827
PARP1 protein, human

Related mentions per year

Related mentions per year

1957-2018
1960198020002020
niraparib
PARP1 protein, human
Poly(ADP-ribose) Polymerase Inhibitors
Piperidines
Indazoles
MK 4827

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
Niraparib is an oral poly(ADP ribose) polymerase (PARP) inhibitor that is currently approved by the United States Food and Drug… (More)
Is this relevant?
2017
2017
Niraparib in Recurrent Ovarian Cancer.
To the Editor: Mirza and colleagues (Dec. 1 issue)1 report encouraging results regarding niraparib maintenance therapy in… (More)
Is this relevant?
Review
2017
Review
2017
Niraparib for the treatment of ovarian cancer.
INTRODUCTION Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors are being developed in maintenance and recurrence… (More)
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
BACKGROUND Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2015
2015
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.
Poly(ADP-ribose) polymerases (PARPs) are involved in DNA repair following damage by endogenous or exogenous processes. It has… (More)
Is this relevant?
2015
2015
Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status
Cells with homologous recombination (HR) deficiency, most notably caused by mutations in the BRCA1 or BRCA2 genes, are sensitive… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Anti-PARP drugs were initially developed as catalytic inhibitors to block the repair of DNA single-strand breaks. We recently… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2014
2014
Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells
The aim of this study was to assess niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase (PARP) inhibitor, for its ability to… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
BACKGROUND Poly(ADP-ribose) polymerase (PARP) is implicated in DNA repair and transcription regulation. Niraparib (MK4827) is an… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
Small-molecule inhibitors of PARP are thought to mediate their antitumor effects as catalytic inhibitors that block repair of DNA… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?